Your browser doesn't support javascript.
loading
(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.
Rosas, Juan C; Aguado-Barrera, Miguel E; Azria, David; Briers, Erik; Elliott, Rebecca; Farcy-Jacquet, Marie-Pierre; Giraldo, Alexandra; Gutiérrez-Enríquez, Sara; Rancati, Tiziana; Rattay, Tim; Reyes, Victoria; Rosenstein, Barry; De Ruysscher, Dirk; Sperk, Elena; Stobart, Hilary; Talbot, Christopher; Vega, Ana; Taboada-Valladares, Begoña; Veldeman, Liv; Ward, Tim; Webb, Adam; West, Catharine; Chang-Claude, Jenny; Seibold, Petra.
Affiliation
  • Rosas JC; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Aguado-Barrera ME; Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians University, Munich, Germany.
  • Azria D; Instituto de Investigación Sanitaria de Santiago de Compostela, Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, Spain.
  • Briers E; University of Montpellier, INSERM U1194 IRCM, Institut du Cancer Montpellier (ICM), Montpellier, France.
  • Elliott R; Patient advocate, Hasselt, Belgium.
  • Farcy-Jacquet MP; University of Manchester, Manchester, UK.
  • Giraldo A; Federation Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut du Cancer Du Gard (ICG), CHU Carémeau, Nîmes, France.
  • Gutiérrez-Enríquez S; Radiation Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Rancati T; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Rattay T; Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy.
  • Reyes V; University of Leicester, Leicester, UK.
  • Rosenstein B; Radiation Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • De Ruysscher D; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Sperk E; Maastro Clinic, Maastricht, The Netherlands.
  • Stobart H; KU Leuven, Leuven, Belgium.
  • Talbot C; Universitätsmedizin Mannheim, Mannheim Cancer Center, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Vega A; Independent Cancer Patients' Voice, London, UK.
  • Taboada-Valladares B; University of Leicester, Leicester, UK.
  • Veldeman L; Instituto de Investigación Sanitaria de Santiago de Compostela, Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, Spain.
  • Ward T; Biomedical Network on Rare Diseases (CIBERER), Seville, Spain.
  • Webb A; Instituto de Investigación Sanitaria de Santiago de Compostela, Fundación Pública Galega de Medicina Xenómica (FPGMX), Santiago de Compostela, Spain.
  • West C; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
  • Chang-Claude J; Ghent University Hospital, Ghent, Belgium.
  • Seibold P; Ghent University, Ghent, Belgium.
Int J Cancer ; 153(9): 1579-1591, 2023 11 01.
Article in En | MEDLINE | ID: mdl-37403702
ABSTRACT
Fatigue is common in breast-cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long-term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI-20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post-RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI-20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P < .05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI-20 fatigue dimensions (ORGeneralFatigue = 3.81, P < .001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Sleep Initiation and Maintenance Disorders Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Int J Cancer Year: 2023 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Sleep Initiation and Maintenance Disorders Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Int J Cancer Year: 2023 Document type: Article Affiliation country: Alemania